Skip to content

Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies

A Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00456872
Enrollment
49
Registered
2007-04-05
Start date
2004-12-31
Completion date
2007-09-30
Last updated
2017-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Pain during injection of the pre-procedure anesthetic

Brief summary

Oncology patients require numerous invasive procedures throughout their disease process including bone marrow biopsies (BMB). BMB.s are performed by a significant number of health care providers. One of the biggest concerns for health care providers is to improve patient comfort. The goal of this study was to reduce pain during BMBs. Specific aims of the study were to determine if there is a difference in patients' perceived pain during injection of the pre-procedure anesthetic when buffered versus unbuffered lidocaine is administered to patient's receiving bone marrow biopsies. A double blind, experimental crossover design was used to examine the difference in pain levels when using buffered versus unbuffered lidocaine prior to the bilateral bone marrow biopsy procedure. Based on a power analysis for a paired t-test, a convenience sample of 48 patients was enrolled into the study. Patients served as their own control. The site of first biopsy, and which lidocaine solution was administered first, were randomized. A 100mm visual analogue scale (VAS) was used to measure pain. All data has been collected, are currently under analysis, and results will be completed in August 2006. Differences in groups will be examined using a paired t-test. A demographic questionnaire was used to gather select demographic variables. Correlative studies will be done to examine the relationship between the patient's perceived pain scores and several exploratory variables. Results of this study may change the current type of anesthetic used pre-BMBs thus improving patient comfort.

Interventions

DRUGlidocaine

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any newly diagnosed patient at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute whose Hematologist or Oncologist has ordered them to undergo a bilateral bone marrow biopsy for diagnostic and /or treatment purposes. * 18 years of age or older.

Exclusion criteria

* Pregnant or Lactating women. * Patients with allergies to local anesthetics. * Patients requiring a unilateral bone marrow biopsy. * Patients that cannot lie flat in either the supine or prone position. * Patients that have used any of the following: narcotics, non-narcotic analgesia or an anti-anxiolytic medication on the same calendar day as the scheduled procedure. These medications will not be given to the participant at any time before or during the procedure. * Patients on long-acting narcotic medication. * Patients with neuropathy in the posterior iliac crest area * Patients with a platelet count less than 20,000. * Patients who are cognitively impaired or unable to self-report pain using the VAS. * Patients with known bone metastasis.

Design outcomes

Primary

MeasureTime frameDescription
Difference in patients perceived pain during injection of the pre-procedure anestheticUp to 24 monthsDetermine difference in patients perceived pain during injection of pre-procedure anesthetic when buffered versus unbuffered lidocaine is administered.

Secondary

MeasureTime frameDescription
Change in pain level over time after anesthetic is administered.Up to 24 monthsDetermine if pain levels change over time after anesthetic is administered.
Investigate relationships between patients perceived pain scores and variables.Up to 24 monthsVariables include gender, ethnicity, stage and extent of disease, body mass index, history of pain tolerance, and perceived emotional support.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026